Small Cell Lung Cancer (SCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Questions: Discounts, Updates etc.

Pages: 79

Price (Single): $3,500

Price (Departmental): $7,000

Price (Company): $10,500

Publication Date: 12-Sep-2011

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports


Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *


The report is an essential source of information and analysis on the global SCLC therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global SCLC therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by our team of industry experts.

Our company analysis estimated the small cell lung cancer (SCLC) therapeutics market to be worth $277.8m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 3.4% over the next eight years to reach $362.3m in 2018. The growth during 2005-2010 was primarily attributed to the launch of an oral form of Hycamtin (topotecan). The steady growth rate during the forecast period is attributed to the expected launch of Amrubicin (SM-5887) in the US and Europe for the treatment of relapse/refractory SCLC patients, as well as a weak late stage pipeline with no molecules to treat newly diagnosed patients.


The report provides information on the key drivers and challenges of the SCLC therapeutics market. Its scope includes -

  • Annual data on the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for SCLC therapeutics, with historic data from 2005 to 2010 and forecasts to 2018.
  • Pipeline analysis data providing information on the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for SCLC fall under major therapeutic classes such as topoisomerase II inhibitors, Pan Bcl-2 inhibitors, topoisomerase I inhibitors, IGF-R1 inhibitors/hedgehog pathway inhibitors, and tyrosine kinase inhibitors.
  • Analysis of the current and future competition in the global SCLC market is provided. The key market players covered are Celgene Corporation and Cephalon Inc.
  • An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics coverage, including strategic a competitor assessment, market characterization and unmet needs analysis, as well as their implications for the SCLC therapeutics market.
  • Analysis of key recent licensing and partnership agreements in the SCLC therapeutics market.

    Reasons to buy

    The report will enhance your decision making capability. It will allow you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global SCLC therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global SCLC therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global SCLC therapeutics market landscape? – Identify, understand and capitalize.
  • Table of Contents

  • 1 Table of contents
  • 1 Table of contents 3
  • 2 Small Cell Lung Cancer (SCLC) Therapeutics - Introduction 7
  • 3 Small Cell Lung Cancer Therapeutics - Market Characterization 17
  • 4 SCLC Therapeutics Market - Competitive Assessment 39
  • 5 SCLC Therapeutics Market - Pipeline Assessment 46
  • 6 Small Cell Lung Cancer Therapeutics - Clinical Trials Mapping 57
  • 7 Small Cell Lung Cancer Therapeutics - Strategic Assessment 63
  • 8 Small Cell Lung Cancer Therapeutics - Future Players in The Market 64
  • 9 Small Cell Lung Cancer Therapeutics - Licensing and Partnership Deals 71
  • 10 Small Cell Lung Cancer Therapeutics - Appendix 73
  • 1.1 List of Tables
  • 1.2 List of Figures
  • Other users found this report page using the following search terms: Market forecast revenues unmet need drivers barriers pharma clinical trials marketed products pipeline promising drugs future players key companies strategic competitor assessment market characterization implications for future market mechanism of action. sclc industry sclcmolecularprofile trend new development drug smallcellcarcinomamarketsize unmetneedextensivesclc sclcmarketsizeusa

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

    Refund and Cancellation Policy: The descriptions of the products and services sold on are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.

    All reports are subject to copyright